2011
DOI: 10.1016/s1473-3099(11)70168-2
|View full text |Cite
|
Sign up to set email alerts
|

Monitoring of HIV viral loads, CD4 cell counts, and clinical assessments versus clinical monitoring alone for antiretroviral therapy in rural district hospitals in Cameroon (Stratall ANRS 12110/ESTHER): a randomised non-inferiority trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

8
105
2

Year Published

2012
2012
2020
2020

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 91 publications
(115 citation statements)
references
References 21 publications
8
105
2
Order By: Relevance
“…In total, nine studies were fully reviewed and four were excluded for the following reasons: two focused solely on patients taking anti-retroviral therapy (ART) (Kunutsor et al, 2011;Laurent et al, 2011), one examined the effect of a housing intervention (not a healthcare intervention) (Kidder et al, 2007) and one study (L.I. Gardner et al, 2009) was excluded as it reported secondary analysis of a study included in the review (L.I.…”
Section: Description Of Studiesmentioning
confidence: 99%
“…In total, nine studies were fully reviewed and four were excluded for the following reasons: two focused solely on patients taking anti-retroviral therapy (ART) (Kunutsor et al, 2011;Laurent et al, 2011), one examined the effect of a housing intervention (not a healthcare intervention) (Kidder et al, 2007) and one study (L.I. Gardner et al, 2009) was excluded as it reported secondary analysis of a study included in the review (L.I.…”
Section: Description Of Studiesmentioning
confidence: 99%
“…Where viral load monitoring is unavailable, clinical monitoring and CD4 monitoring are recommended (205). Although a systematic review of two randomized controlled trials (184,206) provide moderate-quality evidence of mortality and morbidity benefits with CD4 and clinical monitoring compared with routine clinical monitoring in adults receiving ART, these trials largely focused on CD4 and clinical monitoring in people who initiated ART at CD4 counts below 200 cells/mm 3 (Web Annex www.who.int/hiv/pub/guidelines/arv2013/annexes).…”
Section: Immunological Monitoring Versus Clinical Monitoringmentioning
confidence: 99%
“…The resistance testing is actually an HIV-1 genotyping assay where the protease and the reverse transcriptase conserved regions of the pol gene are amplified and sequenced, as described by Fokam et al [107]. Only two commercial tests approved by the Food and Drug Administration are currently available, and have been used widely to follow-up patients under antiretroviral treatment [108,109,110] and to report drug resistance mutations in HIV-1 reverse transcriptase or protease [109,111,112]. However, such commercial kits are very expensive for resource-limited countries like those of Central Africa and also their performance is questionable because of the great diversity of strains found in that region.…”
Section: Pcr Allows the Management Of Hiv Infectionmentioning
confidence: 99%